（1）上海市科技委员会, 上海市浦江人才计划，适时精准靶向CCNE1从而增强卵巢癌免疫治疗效果的机制研究，2025-12-01至2027-11-30，30万，在研，主持

（2）国家自然科学基金委员会，青年项目，82303869，KRAS(G12D)突变通过视神经蛋白 (OPTN)负向调控线粒体自噬导致卵巢癌免疫治疗抵抗的机制研究，2024-01-01 至 2026-12-31, 30万元, 在研, 主持

（3）上海市科技委员会, 上海市2023年度“科技创新行动计划”启明星项目申报指南 / 启明星培育(扬帆专项), 23YF1433400, 靶向RB1阳性卵巢癌的新型策略研究, 2024-04 至 2026-03, 20万元, 在研, 主持

（4）同济大学，附属妇产科医院, 院级课题, 2022RC08, CDK4/6抑制剂联合治疗卵巢癌的新型策略研究,2022-11 至 2025-11, 50万元, 在研, 主持

（5）国家重点研发，合成生物专项，2024YFA0917700，代谢标志物高性能合成生物荧光传感系统创建和应用，在研，参与

（6）上海市浦东新区卫健委联合攻关项目，PW2023D-14，2023，鉑敏感⾸次复发性卵巢癌的精准治疗策略研究，在研，参与

（1）上海市科技委员会, 上海市浦江人才计划，适时精准靶向CCNE1从而增强卵巢癌免疫治疗效果的机制研究，2025-12-01至2027-11-30，30万，在研，主持

（2）国家自然科学基金委员会，青年项目，82303869，KRAS(G12D)突变通过视神经蛋白 (OPTN)负向调控线粒体自噬导致卵巢癌免疫治疗抵抗的机制研究，2024-01-01 至 2026-12-31, 30万元, 在研, 主持

（3）上海市科技委员会, 上海市2023年度“科技创新行动计划”启明星项目申报指南 / 启明星培育(扬帆专项), 23YF1433400, 靶向RB1阳性卵巢癌的新型策略研究, 2024-04 至 2026-03, 20万元, 在研, 主持

（4）同济大学，附属妇产科医院, 院级课题, 2022RC08, CDK4/6抑制剂联合治疗卵巢癌的新型策略研究,2022-11 至 2025-11, 50万元, 在研, 主持

（5）国家重点研发，合成生物专项，2024YFA0917700，代谢标志物高性能合成生物荧光传感系统创建和应用，在研，参与

（6）上海市浦东新区卫健委联合攻关项目，PW2023D-14，2023，鉑敏感⾸次复发性卵巢癌的精准治疗策略研究，在研，参与

一、（代表性论著:#Co-corresponding）

(1) Jindan Sheng; Susumu Kohno; Nobuhiro Okada; Nobuyuki Okahashi; Kana Teranishi; FumioMatsuda; Hiroshi Shimizu; Paing Linn; Naoko Nagatani; Minako Yamamura; Kenichi Harada; Shin-ichiHorike; Hiroshi Inoue; Seiji Yano; Sharad Kumar; Shunsuke Kitajima; Itsuki Ajioka; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-DependentKinase 4/6 Inhibitor Combination Therapy, HEPATOLOGY, 2021, 74(4): 1971-1993.IF=17.298

(2)Paing Linn; Susumu Kohno; Jindan Sheng; Nilakshi Kulathunga; Hai Yu; Zhiheng Zhang;Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi ; Targeting RB1 Loss in Cancers, cancers,2021, 13(15): 3737.IF=6.575 

(3) Mingjun Ma; Chao Wang; Meixuan Wu; Sijia Gu; Jiani Yang; Yue Zhang; Shanshan Cheng;Shilin Xu; Minghai Zhang; Yongsong Wu; Yaqian Zhao; Xiu Tian; Dominic Chih-Cheng Voon; ChiakiTakahashi; Jindan Sheng#; Yu Wang# .CSGALNACT2 restricts ovarian cancer migration and invasion bymodulating MAPK/ERK pathway through DUSP1, Cellular Oncology, 2023, 903(9): 13402.IF=6.6

(4) Xiaomei Luo; Yingjie Wang; Hao Zhang; Guangquan Chen; Jindan Sheng; Xiu Tian; Renhao Xue;Yu Wang .Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-RelatedGenes Suggesting a Potential Role for FBXO9, Biomolecules, 2023, 13(12): 1724.IF=4.8

(5) Jiani Yang; Chao Wang; Yue Zhang; Shanshan Cheng; Meixuan Wu; Sijia Gu; Shilin Xu;Yongsong Wu; Jindan Sheng; Dominic Chih-Cheng Voon; Yu Wang.Clinical significance and immuneinfiltration analyses of a novel coagulation-related signature in ovarian cancer, Cancer Cell International, 2023, 23(1).IF=5.3

(6)Hao Zhang, Xiaomei Luo, Shiwei Li, Yingjie Wang, Yutong Gao, Yaodi Shao, Haixia Huang, Jindan Sheng, Xiu Tian, Fang Bai, Gaofeng Fan, Renhao Xue, Yu Wang, Targeting CDK 9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian Cancer, Phytotherapy Research, 2025,38(8),3648-3663.IF=6.3

(7)Yuanyuan Zhang, Susumu Kohno, Keqi Gao,Mahadi Hasan, Tomohisa Baba, Zixue Zhang, Nao Sankoda, Hai Yu, Junjian Pan,Noriko Gotoh, Makoto Nakanishi, Yasuhiro Yamada, Jindan Sheng, Takiko Daikoku, YoshikazuJohmura & Chiaki Takahashi;Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition, Cell Death and Differentiation,2025.IF=15.4

(8)Mingjun Ma , Xiu Tian, Weiwei Cao, Chao Wang, Yue Zhang, Jiani Yang, Shanshan Cheng, Sijia Gu, Jianxiao Li, Yaqian Zhao, Yaodi Shao, Chao Huang, Shuo Shi, Renhao Xue, Chen Chu, Jindan Sheng#, Yu Wang#,CRISP3, a Potential Tumor Suppressor, Inhibits the Progression of High-Grade Serous Ovarian Carcinoma by Modulating the PI3K/AKT Pathway. Biomedicines. 2026 Feb 20;14(2):471. IF=4

(9)Mingjun Ma, Chao Wang, Yue Zhang,Shanshan Cheng, Jiani Yang, Yejun Zou, XiuTian, Sijia Gu, Jianxiao Li, Weiwei Cao,Chao Huang, Yaodi Shao, Yaqian Zhao, YutongGao, Yilin Liu, Wen Pang, Shuo Shi,Hui Ding, Minghai Zhang, Feiyi Cai,Yongsong Wu, Renhao Xue, Xiawei Cheng, ChenChu, Jindan Sheng#, Yu Wang#, Targeting EZH2-Driven Cholesterol Metabolic Vulnerabilitythrough Napabucasin Suppresses Ovarian Cancer Metastasis.Cell Death & Disease. 2026，April 17th, Accepted, IF=9.6

二、专利:

(1) 高橋 智聡; 河野 晋; 盛金丹 ; RB1陽性癌の治療用医薬組成物及びキット, 2020-10-28, 日本,特願2020-180429 (授权号：特 許 第 7 5 7 9 5 6 4 )

(2) 王育; 盛金丹; 顾思佳; 吴美璇 ; 一种治疗 kras 突变的卵巢癌的组合药物及其应用, 2023-5-31,中国, 202310374305.8 (授权号：2026050100361250)

(3) 王育; 盛金丹; 张越; 汪超 ; 一种治疗 CCNE1 异常扩增型卵巢癌的药物组合物及其应用, 2023-12-6, 中国, 202311658341.3 (专利)

(4) 王育; 盛金丹; 吴美璇; 顾思佳 ; 一种治疗 RB1 阳性的卵巢癌的组合药物及其应用, 2023-6-6, 中国, 202310374279.9 (专利)

(5)王育;盛金丹;马明军;EZH2 在卵巢癌诊断试剂和治疗药物中的应用,2025-03-27，中国，202510375911.0（专利）

三、参加或组织的学术会议

（1）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 43rd Annual Meetingof the Molecular Biology Society of Japan (MBSJ2020 Online) , 线上, 2020-12-2至2020-12-4 (会议报告)

（2）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, 2021 the JapaneseSociety of Medical Oncology Annual Meeting (JSMO2021), 线上, 2021-2-18至2021-2-21 (会议报告)

（3）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, AACR ANNUAL MEETING2021 2021/4/10-2021/4/15, 线上, 2021-4-10至2021-4-15 (会议报告)

（4）Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact HepatocellularCarcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 80th Annual Meetingof the Japanese Cancer Association 2021/09/30-2021/10/02, 线上, 2021-9-30至2021-10-2 (会议报告)

（5）Jindan Sheng; Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi；Yu Wang; Gynecologic Oncology Symposium，2023,上海市第一妇婴保健院行政楼308室.

（6）Jindan Sheng; Cancer Biology Retreat 2024，Broad Institute of MIT and Harvard，Dana-Farber Cancer Institute; Department of Cancer Biology.

（7）MGH Molecular Biology & HMS Genetics 2024， Omni Mount Washington Hotel Bretton Woods, NH Massachusetts General Hospital and Harvard Medical School.

四、学术奖励

（1） Jindan Sheng(1/1); A targetable NF-κB−LCN2 axis controls liver tumorigenesis, 中国驻日本大使馆, 其他, 国际学术奖, 2022(Jindan Sheng) (科研奖励)

（2）盛金丹(1/1); 肝細胞がんの分子機序解明と新規治療法開発, 日本学政, 其他, 其他, 2021(盛金丹) (科研奖励)

1.Medical Tribune(https://medical-tribune.co.jp/news/2021/0902538229/)

2.EurekAlert (https://www.eurekalert.org/news-releases/927204)

3.Asia RESEARCHNEWS(-https://www.asiaresearchnews.com/content/new-therapeutic-method-combined-synthetic-cd)

4.Hokkoku Shimbun Kanazawa University latest Research News(-https://www.kanazawa-u.ac.jp/latest-research/95792).